Langenbeck's Archives of Surgery

, Volume 394, Issue 1, pp 105–113

Occult disseminated tumor cells in lymph nodes of patients with gastric carcinoma. A critical appraisal of assessment and relevance

  • Peter Scheunemann
  • Nikolas H. Stoecklein
  • Kai Hermann
  • Alexander Rehders
  • Claus F. Eisenberger
  • Wolfram T. Knoefel
  • Stefan B. Hosch
Original Article


Background and aims

In gastric cancer, regional lymph node metastasis verified by histopathological examination is the most important prognostic factor after complete surgical tumor resection (R0). However, the prognostic value of immunohistochemically identifiable disseminated tumor cells in lymph nodes without histopathological tumor burden in patients with gastric cancer is still controversially discussed. The aim of the study was to assess the frequency and prognostic impact of minimal tumor cell spread to lymph nodes in these patients.


One hundred sixty lymph nodes judged as “tumor free” on routine histopathology obtained from 58 patients with gastric adenocarcinoma were analyzed immunohistochemically using the monoclonal anti-EpCAM antibody Ber-EP4 for occult disseminated tumor cells.


Tumor cells in lymph nodes were detected in 62 (38.8%) of the 160 “tumor-free” lymph nodes obtained from 39 (67.2%) patients. Multivariate Cox regression analysis confirmed the presence of disseminated tumor cells in “tumor-free” lymph nodes as an independent prognostic factor for both a significantly reduced relapse-free survival (p = 0.008) and overall survival (p = 0.009).


The frequent occurrence and prognostic impact of minimal disseminated tumor cells in lymph nodes of patients with gastric carcinoma support the need for a refined staging system of excised lymph nodes, which should include immunohistochemical examination.


Disseminated tumor cells Micrometastasis Minimal residual disease Lymph nodes Gastric carcinoma 


  1. 1.
    Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC et al (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353:793–802 doi:10.1056/NEJMoa050434 PubMedCrossRefGoogle Scholar
  2. 2.
    Lindemann F, Schlimok G, Dirschedl P, Witte J, Riethmuller G (1992) Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients. Lancet 340:685–689 doi:10.1016/0140-6736(92)92230-D PubMedCrossRefGoogle Scholar
  3. 3.
    Seeliger H, Spatz H, Jauch KW (2003) Minimal residual disease in gastric cancer. Recent Results Cancer Res 162:79–87PubMedGoogle Scholar
  4. 4.
    van Heek NT, Tascilar M, van Beekveld JL, Drillenburg P, Offerhaus GJ, Gouma DJ (2001) Micrometastases in bone marrow of patients with suspected pancreatic and ampullary cancer. Eur J Surg Oncol 27:740–745 doi:10.1053/ejso.2001.1209 PubMedCrossRefGoogle Scholar
  5. 5.
    Bonavina L, Ferrero S, Midolo V, Buffa R, Cesana B, Peracchia A (1999) Lymph node micrometastases in patients with adenocarcinoma of the esophagogastric junction. J Gastrointest Surg 3:468–476 doi:10.1016/S1091-255X(99)80099-7 PubMedCrossRefGoogle Scholar
  6. 6.
    Calaluce R, Miedema BW, Yesus YW (1998) Micrometastasis in colorectal carcinoma: a review. J Surg Oncol 67:194–202 doi:10.1002/(SICI)1096-9098(199803)67:3<194::AID-JSO11>3.0.CO;2-2 PubMedCrossRefGoogle Scholar
  7. 7.
    Cote RJ, Peterson HF, Chaiwun B, Gelber RD, Goldhirsch A, Castiglione-Gertsch M et al (1999) Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. Lancet 354:896–900 doi:10.1016/S0140-6736(98)11104-2 PubMedCrossRefGoogle Scholar
  8. 8.
    Greenson JK, Isenhart CE, Rice R, Mojzisik C, Houchens D, Martin EW Jr (1994) Identification of occult micrometastases in pericolic lymph nodes of Duke’s B colorectal cancer patients using monoclonal antibodies against cytokeratin and CC49. Correlation with long-term survival. Cancer 73:563–569 doi:10.1002/1097-0142(19940201)73:3<563::AID-CNCR2820730311>3.0.CO;2-D PubMedCrossRefGoogle Scholar
  9. 9.
    Hosch S, Kraus J, Scheunemann P, Izbicki JR, Schneider C, Schumacher U et al (2000) Malignant potential and cytogenetic characteristics of occult disseminated tumor cells in esophageal cancer. Cancer Res 60:6836–6840PubMedGoogle Scholar
  10. 10.
    Hosch SB, Knoefel WT, Metz S, Stoecklein N, Niendorf A, Broelsch CE et al (1997) Early lymphatic tumor cell dissemination in pancreatic cancer: frequency and prognostic significance. Pancreas 15:154–159 doi:10.1097/00006676-199708000-00007 PubMedCrossRefGoogle Scholar
  11. 11.
    Komukai S, Nishimaki T, Suzuki T, Kanda T, Kuwabara S, Hatakeyama K (2002) Significance of immunohistochemical nodal micrometastasis as a prognostic indicator in potentially curable oesophageal carcinoma. Br J Surg 89:213–219PubMedGoogle Scholar
  12. 12.
    Kubuschok B, Passlick B, Izbicki JR, Thetter O, Pantel K (1999) Disseminated tumor cells in lymph nodes as a determinant for survival in surgically resected non-small-cell lung cancer. J Clin Oncol 17:19–24PubMedGoogle Scholar
  13. 13.
    Liefers GJ, Cleton-Jansen AM, van de Velde CJ, Hermans J, van Krieken JH, Cornelisse CJ et al (1998) Micrometastases and survival in stage II colorectal cancer. N Engl J Med 339:223–228 doi:10.1056/NEJM199807233390403 PubMedCrossRefGoogle Scholar
  14. 14.
    Lindblom A (1998) Improved tumor staging in colorectal cancer. N Engl J Med 339:264–265 doi:10.1056/NEJM199807233390410 PubMedCrossRefGoogle Scholar
  15. 15.
    McGuckin MA, Cummings MC, Walsh MD, Hohn BG, Bennett IC, Wright RG (1996) Occult axillary node metastases in breast cancer: their detection and prognostic significance. Br J Cancer 73:88–95PubMedGoogle Scholar
  16. 16.
    Passlick B, Izbicki JR, Kubuschok B, Nathrath W, Thetter O, Pichlmeier U et al (1994) Immunohistochemical assessment of individual tumor cells in lymph nodes of patients with non-small-cell lung cancer. J Clin Oncol 12:1827–1832PubMedGoogle Scholar
  17. 17.
    Trojani M, de Mascarel I, Coindre JM, Bonichon F (1987) Micrometastases to axillary lymph nodes from invasive lobular carcinoma of breast: detection by immunohistochemistry and prognostic significance. Br J Cancer 56:838–839PubMedGoogle Scholar
  18. 18.
    Adachi Y, Kamakura T, Mori M, Baba H, Maehara Y, Sugimachi K (1994) Prognostic significance of the number of positive lymph nodes in gastric carcinoma. Br J Surg 81:414–416 doi:10.1002/bjs.1800810331 PubMedCrossRefGoogle Scholar
  19. 19.
    Bozzetti F, Bonfanti G, Morabito A, Bufalino R, Menotti V, Andreola S et al (1986) A multifactorial approach for the prognosis of patients with carcinoma of the stomach after curative resection. Surg Gynecol Obstet 162:229–234PubMedGoogle Scholar
  20. 20.
    Maruyama K, Okabayashi K, Kinoshita T (1987) Progress in gastric cancer surgery in Japan and its limits of radicality. World J Surg 11:418–425 doi:10.1007/BF01655804 PubMedCrossRefGoogle Scholar
  21. 21.
    Siewert JR, Bottcher K, Stein HJ, Roder JD (1998) Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 228:449–461 doi:10.1097/00000658-199810000-00002 PubMedCrossRefGoogle Scholar
  22. 22.
    Lim L, Michael M, Mann GB, Leong T (2005) Adjuvant therapy in gastric cancer. J Clin Oncol 23:6220–6232 doi:10.1200/JCO.2005.11.593 PubMedCrossRefGoogle Scholar
  23. 23.
    Izbicki JR, Hosch SB, Pichlmeier U, Rehders A, Busch C, Niendorf A et al (1997) Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. N Engl J Med 337:1188–1194 doi:10.1056/NEJM199710233371702 PubMedCrossRefGoogle Scholar
  24. 24.
    Hosch SB, Stoecklein NH, Izbicki JR (2003) Molecular markers and staging of early esophageal cancer. Langenbecks Arch Surg 388:77–82PubMedGoogle Scholar
  25. 25.
    Latza U, Niedobitek G, Schwarting R, Nekarda H, Stein H (1990) Ber-EP4: new monoclonal antibody which distinguishes epithelia from mesothelial. J Clin Pathol 43:213–219 doi:10.1136/jcp.43.3.213 PubMedCrossRefGoogle Scholar
  26. 26.
    Hermanek P, Sobin LH (eds) (1992) In: UICC: TNM classification of malignant tumours. 4th edn. Springer, Berlin 2nd revGoogle Scholar
  27. 27.
    Sobin LH, Wittekind C (eds) (1997) In: TNM classification of malignant tumors. 5th edn. Wiley, New YorkGoogle Scholar
  28. 28.
    Lauren P (1965) The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 64:31–49PubMedGoogle Scholar
  29. 29.
    Scheunemann P, Stoecklein NH, Rehders A, Bidde M, Metz S, Peiper M et al (2008) Occult tumor cells in lymph nodes as a predictor for tumor relapse in pancreatic adenocarcinoma. Langenbecks Arch Surg 393:359–365PubMedCrossRefGoogle Scholar
  30. 30.
    Choi HJ, Kim YK, Kim YH, Kim SS, Hong SH (2002) Occurrence and prognostic implications of micrometastases in lymph nodes from patients with submucosal gastric carcinoma. Ann Surg Oncol 9:13–19 doi:10.1245/aso.2002.9.1.13 PubMedCrossRefGoogle Scholar
  31. 31.
    Fukagawa T, Sasako M, Mann GB, Sano T, Katai H, Maruyama K et al (2001) Immunohistochemically detected micrometastases of the lymph nodes in patients with gastric carcinoma. Cancer 92:753–760 doi:10.1002/1097-0142(20010815)92:4<753::AID-CNCR1379>3.0.CO;2-5 PubMedCrossRefGoogle Scholar
  32. 32.
    Kikuchi Y, Tsuchiya A, Ando Y, Yoshida T, Takenosita S (1999) Immunohistochemical detection of lymph node microinvolvement in node-negative gastric cancer. Gastric Cancer 2:173–178 doi:10.1007/s101200050042 PubMedCrossRefGoogle Scholar
  33. 33.
    Morgagni P, Saragoni L, Scarpi E, Zattini PS, Zaccaroni A, Morgagni D et al (2003) Lymph node micrometastases in early gastric cancer and their impact on prognosis. World J Surg 27:558–561 doi:10.1007/s00268-003-6797-y PubMedCrossRefGoogle Scholar
  34. 34.
    Cai J, Ikeguchi M, Maeta M, Kaibara N, Sakatani T (1999) Clinicopathological value of immunohistochemical detection of occult involvement in pT3N0 gastric cancer. Gastric Cancer 2:95–100 doi:10.1007/s101200050030 PubMedCrossRefGoogle Scholar
  35. 35.
    Ishida K, Katsuyama T, Sugiyama A, Kawasaki S (1997) Immunohistochemical evaluation of lymph node micrometastases from gastric carcinomas. Cancer 79:1069–1076 doi:10.1002/(SICI)1097-0142(19970315)79:6<1069::AID-CNCR3>3.0.CO;2-B PubMedCrossRefGoogle Scholar
  36. 36.
    Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Higashi H, Watanabe T et al (2003) Clinical impact of micrometastasis of the lymph node in gastric cancer. Am Surg 69:573–577PubMedGoogle Scholar
  37. 37.
    Lee E, Chae Y, Kim I, Choi J, Yeom B, Leong AS (2002) Prognostic relevance of immunohistochemically detected lymph node micrometastasis in patients with gastric carcinoma. Cancer 94:2867–2873 doi:10.1002/cncr.10562 PubMedCrossRefGoogle Scholar
  38. 38.
    Maehara Y, Oshiro T, Endo K, Baba H, Oda S, Ichiyoshi Y et al (1996) Clinical significance of occult micrometastasis lymph nodes from patients with early gastric cancer who died of recurrence. Surgery 119:397–402 doi:10.1016/S0039-6060(96)80138-3 PubMedCrossRefGoogle Scholar
  39. 39.
    Nakajo A, Natsugoe S, Ishigami S, Matsumoto M, Nakashima S, Hokita S et al (2001) Detection and prediction of micrometastasis in the lymph nodes of patients with pN0 gastric cancer. Ann Surg Oncol 8:158–162 doi:10.1007/s10434-001-0158-6 PubMedCrossRefGoogle Scholar
  40. 40.
    Yasuda K, Adachi Y, Shiraishi N, Inomata M, Takeuchi H, Kitano S (2002) Prognostic effect of lymph node micrometastasis in patients with histologically node-negative gastric cancer. Ann Surg Oncol 9:771–774PubMedCrossRefGoogle Scholar
  41. 41.
    Franke WW, Moll R (1987) Cytoskeletal components of lymphoid organs. I. Synthesis of cytokeratins 8 and 18 and desmin in subpopulations of extrafollicular reticulum cells of human lymph nodes, tonsils, and spleen. Differentiation 36:145–163 doi:10.1111/j.1432-0436.1987.tb00189.x PubMedCrossRefGoogle Scholar
  42. 42.
    Domagala W, Bedner E, Chosia M, Weber K, Osborn M (1992) Keratin-positive reticulum cells in fine needle aspirates and touch imprints of hyperplastic lymph nodes. A possible pitfall in the immunocytochemical diagnosis of metastatic carcinoma. Acta Cytol 36:241–245PubMedGoogle Scholar
  43. 43.
    Gown AM, Boyd HC, Chang Y, Ferguson M, Reichler B, Tippens D (1988) Smooth muscle cells can express cytokeratins of “simple” epithelium. Immunocytochemical and biochemical studies in vitro and in vivo. Am J Pathol 132:223–232PubMedGoogle Scholar
  44. 44.
    Kubota K, Nakanishi H, Hiki N, Shimizu N, Tsuji E, Yamaguchi H et al (2003) Quantitative detection of micrometastases in the lymph nodes of gastric cancer patients with real-time RT-PCR: a comparative study with immunohistochemistry. Int J Cancer 105:136–143 doi:10.1002/ijc.11031 PubMedCrossRefGoogle Scholar
  45. 45.
    Matsumoto M, Natsugoe S, Ishigami S, Nakashima S, Nakajo A, Miyazono F et al (2002) Lymph node micrometastasis and lymphatic mapping determined by reverse transcriptase-polymerase chain reaction in pN0 gastric carcinoma. Surgery 131:630–635 doi:10.1067/msy.2002.124632 PubMedCrossRefGoogle Scholar
  46. 46.
    Okada Y, Fujiwara Y, Yamamoto H, Sugita Y, Yasuda T, Doki Y et al (2001) Genetic detection of lymph node micrometastases in patients with gastric carcinoma by multiple-marker reverse transcriptase-polymerase chain reaction assay. Cancer 92:2056–2064 doi:10.1002/1097-0142(20011015)92:8<2056::AID-CNCR1545>3.0.CO;2-L PubMedCrossRefGoogle Scholar
  47. 47.
    Sonoda H, Yamamoto K, Kushima R, Okabe H, Tani T (2004) Detection of lymph node micrometastasis in gastric cancer by MUC2 RT-PCR: usefulness in pT1 cases. J Surg Oncol 88:63–70 doi:10.1002/jso.20143 PubMedCrossRefGoogle Scholar
  48. 48.
    Bostick PJ, Chatterjee S, Chi DD, Huynh KT, Giuliano AE, Cote R et al (1998) Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients. J Clin Oncol 16:2632–2640PubMedGoogle Scholar
  49. 49.
    Jung R, Petersen K, Kruger W, Wolf M, Wagener C, Zander A et al (1999) Detection of micrometastasis by cytokeratin 20 RT-PCR is limited due to stable background transcription in granulocytes. Br J Cancer 81:870–873 doi:10.1038/sj.bjc.6690778 PubMedCrossRefGoogle Scholar
  50. 50.
    Ko Y, Klinz M, Totzke G, Gouni-Berthold I, Sachinidis A, Vetter H (1998) Limitations of the reverse transcription-polymerase chain reaction method for the detection of carcinoembryonic antigen-positive tumor cells in peripheral blood. Clin Cancer Res 4:2141–2146PubMedGoogle Scholar
  51. 51.
    Zippelius A, Kufer P, Honold G, Kollermann MW, Oberneder R, Schlimok G et al (1997) Limitations of reverse-transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow. J Clin Oncol 15:2701–2708PubMedGoogle Scholar
  52. 52.
    Liljefors M, Nilsson B, Fagerberg J, Ragnhammar P, Mellstedt H, Frodin JE (2005) Clinical effects of a chimeric anti-EpCAM monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma. Int J Oncol 26:1581–1589PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Peter Scheunemann
    • 1
  • Nikolas H. Stoecklein
    • 1
  • Kai Hermann
    • 2
  • Alexander Rehders
    • 1
  • Claus F. Eisenberger
    • 1
  • Wolfram T. Knoefel
    • 1
  • Stefan B. Hosch
    • 1
  1. 1.Department of General SurgeryUniversity Hospital Düsseldorf, Heinrich-Heine-UniversityDüsseldorfGermany
  2. 2.Department of General SurgeryUniversity Hospital Hamburg-EppendorfHamburgGermany

Personalised recommendations